Posted by Michael Wonder on 17 Nov 2022
Napp announces acceptance of their rezafungin marketing authorisation application for the treatment of invasive candidiasis to the UK Medicines and Healthcare Products Regulatory Agency
16 November 2022 - The MHRA filing is supported by the pivotal ReSTORE Phase 3 clinical trial results, where rezafungin demonstrated non-inferiority to the current standard of care in the treatment of candidaemia and/or invasive candidiasis.
Napp today announces that the MHRA has accepted a marketing authorisation application for rezafungin, a novel echinocandin in clinical development for the treatment of invasive candidiasis in adult patients.
